Department of Dermatology, University of the Philippines , Manila , Philippines.
J Dermatolog Treat. 2014 Feb;25(1):38-45. doi: 10.3109/09546634.2012.742176. Epub 2013 Jan 20.
International consensus statements on the management of scalp psoriasis are available, but no such recommendations exist for Asia.
The Asia Scalp Psoriasis Study Group (ASPSG) met in May 2011 to review the epidemiologic pattern of scalp psoriasis in Southeast Asia and to develop Asia-specific recommendations for its management.
The overall prevalence of psoriasis in Asia is <0.3%, but 75-90% have scalp involvement, whether isolated or with lesions elsewhere, which can negatively impact quality of life (QoL). Treatment decisions should be based primarily on objective disease severity, but should also take account of patient QoL. Psychosocial support and more aggressive treatment should be offered to all patients with moderate to severe QoL impairment. Topical therapy is indicated first-line in all patients, with combination therapy (corticosteroid + calcipotriol), more occlusive formulations, keratolytics, and very potent corticosteroids for patients needing greater or faster efficacy. Systemic therapies, light or laser treatments should be reserved for patients with severe and recalcitrant disease.
The ASPSG recommends a patient-centered approach to scalp psoriasis management, consistent with the international consensus statements. Asian physicians should also consider patient QoL, prior treatment response, formulation preferences, likely adherence, cost, time available for self-management, and potential adverse events.
国际上有关于头皮银屑病管理的共识声明,但亚洲地区尚无此类建议。
亚洲头皮银屑病研究组(ASPSG)于 2011 年 5 月召开会议,旨在回顾东南亚头皮银屑病的流行病学模式,并制定亚洲特有的管理建议。
亚洲的银屑病总患病率<0.3%,但 75-90%的患者存在头皮受累,无论是否孤立存在,病变是否存在于其他部位,均会对生活质量(QoL)产生负面影响。治疗决策应主要基于客观疾病严重程度,但也应考虑患者的 QoL。应向所有中重度 QoL 受损的患者提供心理社会支持和更积极的治疗。在所有患者中,一线治疗均推荐外用药物治疗,联合治疗(皮质类固醇+卡泊三醇)、更具封闭性的制剂、角质松解剂和非常强效的皮质类固醇,适用于需要更大或更快疗效的患者。对于严重和难治性疾病的患者,应保留系统性治疗、光疗或激光治疗。
ASPSG 建议采用以患者为中心的方法来管理头皮银屑病,这与国际共识声明一致。亚洲医生还应考虑患者的 QoL、既往治疗反应、制剂偏好、预期依从性、成本、自我管理的可用时间以及可能的不良反应。